0

Back to Resolving the Daratumumab Interference: A New Reason for Panreactivity in Routine Antibody Screening
Resolving the Daratumumab Interference: A New Reason for Panreactivity in Routine Antibody Screening

Resolving the Daratumumab Interference: A New Reason for Panreactivity in Routine Antibody Screening

Release Date: Mar 2017

CC: PC, MK, PBL, ICS, PR, SBP

Huy P. Pham, MD, MPH
Medical Director of Therapeutic Apheresis and Assistant Professor, University of Alabama at Birmingham, Birmingham, AL

Melissa Cushing, MD
Director of Transfusion Medicine and Cellular Therapy and Associate Director of the Clinical Laboratories, New York Presbyterian Hospital, New York, NY; Associate Professor of Clinical Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY


Description:

Monoclonal antibodies are increasingly being used in the care of patients with a variety of conditions including malignancy, infection, and inflammatory diseases. The interference of monoclonal antibodies with clinical testing is an emerging concern that requires both recognition and the development of appropriate solutions. Daratumumab, a novel anti-CD38 monoclonal antibody, has been recently approved by the FDA in the treatment of patients with multiple myeloma. During clinical trials, its use resulted in panreactivity with routine blood banking compatibility testing. This could affect the identification of irregular alloantibodies for patients requiring blood transfusion. Therefore, it is essential for transfusion services to be aware of these phenomena and to develop solutions to overcome this interference to enhance patient safety. This session provides an introduction to monoclonal antibody therapy, with a focus on daratumumab. The blood bank testing affected by daratumumab's interference will be described, along with possible solutions to overcome the interference using currently available techniques. Finally, examples of how transfusion services across the U.S handle such challenges in conjunction with the clinical service will be reviewed.


After attending this session, participants will be able to:

·        Review the pathogenesis of multiple myeloma and the mechanisms and efficacy of daratumumab in the treatment of myeloma.

·       Outline the potential interference of daratumumab with routine blood bank testing and methods to resolve such interference.

·        Provide examples of protocols on how transfusion services across the U.S handle such challenges.


Who should attend?  Practicing Pathologists, Residents, Doctoral Scientists, Laboratory Managers, Bench Supervisors, Bench Technologists & Technicians

  • List Price: $45.00
  • Member Price: $35.00
 
Want to save more?
Log into see if you qualify for a lower rate.
Members save $10.00 or more Join
Item Details:
Back to Resolving the Daratumumab Interference: A New Reason for Panreactivity in Routine Antibody Screening

Bought This Bought That ...